Investigations of the AstraZeneca vaccine (Vaxzevria)

The Danish Health Authority has decided to continue the COVID-19 vaccine rollout without the vaccine from AstraZeneca. In this theme, you can read about the investigations of the unusual symptoms that were part of the rationale for this decision.

Go to theme

Vaccines against COVID-19

Medicines agencies around the world are collaborating to approve and follow vaccines against COVID-19. Once the vaccines are approved, medicines authorities around the world follow up with monitoring of adverse drug reactions. Read about results, processes and new vaccines against COVID-19 in our three themes or in the question-and-answer below.

Go to theme
indgangsikon nr 1

General public

Here you can read about reimbursement, drugs affecting the ability to drive and other topics relevant for the general public.

indgangsikon nr 2


Information on licensing, inspections, fees, company authorisations, clinical trials and more.

indgangsikon nr 3

Healthcare professionals

This section gathers information for doctors, nurses, pharmacies, dentists and other healthcare professionals.


EMA: Possible link between the Johnson & Johnson vaccine and unusual symptoms

21 April 2021

There is a possible link between the Johnson & Johnson vaccine and unusual symptoms with a combination of blood clots in unusual sites, low levels of blood platelets and several cases of bleeding. A few cases have been observed in the USA. The frequency of these unusual symptoms is still being investigated.

EMA to undertake a review of data as to the AstraZeneca vaccine’s efficacy in preventing COVID-19 disease

15 April 2021

EMA: The AstraZeneca vaccine possibly causes rare, serious symptoms – but remains authorised for use

08 April 2021

COVID-19 Vaccine AstraZeneca: Investigations of blood clots with low numbers of platelets and bleeding continue in Denmark and in the EU

26 March 2021